Clinical Trial Update: PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating parsaclisib combined with chidamide for relapsed/refractory peripheral T-cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Parsaclisib (parsaclisib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Peripheral T-Cell Lymphoma | Phase 1 | Status: TERMINATED